Ohio House passes bill to legalize and tax ‘intoxicating hemp;’ prohibit marijuana use in public places - signalohio.org
Ohio House passes a bill to legalize and tax 'intoxicating hemp' and prohibit marijuana use in public places.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 13, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers, especially those handling hemp-derived compounds or controlled substances, and businesses affected by public marijuana use restrictions. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified; the bill is still in the legislative process.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The Ohio House passed a bill that would legalize and tax 'intoxicating hemp' and prohibit marijuana use in public places. The bill is not yet law; it requires Senate approval and the governor's signature.
Who it affects
Pharmaceutical manufacturers, especially those handling hemp-derived compounds or controlled substances, and businesses affected by public marijuana use restrictions.
What you must do
Monitor the bill's progress through the Ohio Senate and governor's office. Assess potential impacts on product lines involving hemp-derived compounds and ensure compliance with any new public-use restrictions if enacted.
Deadline
Not specified; the bill is still in the legislative process.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness